Convalescent plasma in Covid-19: Possible mechanisms of action
Top Cited Papers
Open Access
- 5 May 2020
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 19 (7), 102554
- https://doi.org/10.1016/j.autrev.2020.102554
Abstract
No abstract availableKeywords
Funding Information
- Universidad del Rosario (ABN-011)
- Universidad CES
This publication has 109 references indexed in Scilit:
- Role of ActivatingFcγRGene Polymorphisms in Kawasaki Disease Susceptibility and Intravenous Immunoglobulin ResponseCirculation: Cardiovascular Genetics, 2012
- Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulinJournal of Allergy and Clinical Immunology, 2011
- Intravenous immunoglobulin up‐regulates the expression of the inhibitory FcγIIB receptor on B cellsImmunology & Cell Biology, 2009
- Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathyProceedings of the National Academy of Sciences of the United States of America, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Clinical Characteristics of 26 Human Cases of Highly Pathogenic Avian Influenza A (H5N1) Virus Infection in ChinaPLOS ONE, 2008
- The management of coronavirus infections with particular reference to SARSJournal of Antimicrobial Chemotherapy, 2008
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- IVIG in autoimmunity and cancer – efficacy versus safetyExpert Opinion on Drug Safety, 2002
- Treatment of West Nile Virus Encephalitis with Intravenous ImmunoglobulinEmerging Infectious Diseases, 2001